

# Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Insight and Forecast to 2026

<https://marketpublishers.com/r/G6B801AB51ACEN.html>

Date: August 2020

Pages: 179

Price: US\$ 2,350.00 (Single User License)

ID: G6B801AB51ACEN

## Abstracts

The research team projects that the Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market size will grow from XXX in 2019 to XXX by 2026, at an estimated CAGR of XX. The base year considered for the study is 2019, and the market size is projected from 2020 to 2026.

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 30 major countries. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

By Market Players:

Novartis

Tarveda Therapeutics

Teva Pharmaceuticals

Pfizer

Exelixis, Inc.

Fresenius Kabi

Hutchison China MediTech Limited

Sun Pharma

**By Type**

Chemotherapy

Peptide-Receptor Radionuclide Therapy

Others

**By Application**

Hospitals

Clinics

Ambulatory Surgical Centers

Others

**By Regions/Countries:**

North America

United States

Canada

Mexico

East Asia

China

Japan

South Korea

Europe

Germany

United Kingdom

France

Italy

South Asia

India

Southeast Asia

Indonesia

Thailand

Singapore

Middle East

Turkey

Saudi Arabia  
Iran

Africa  
Nigeria  
South Africa

Oceania  
Australia

South America

### Points Covered in The Report

The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years data history and forecast.

The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.

Data and information by market player, by region, by type, by application and etc, and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

### Key Reasons to Purchase

To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and its impact in the global market.

Learn about the market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

The report focuses on Global, Top 10 Regions and Top 50 Countries Market Size of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics 2015-2020, and development forecast 2021-2026 including industries, major players/suppliers worldwide and market share by regions, with company and product introduction, position in the market including their market status and development trend by types and applications which will provide its price and profit status, and marketing status & market growth drivers and challenges, with base year as 2019.

#### Key Indicators Analysed

**Market Players & Competitor Analysis:** The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2015-2020 & Sales by Product Types.

**Global and Regional Market Analysis:** The report includes Global & Regional market status and outlook 2021-2026. Further the report provides break down details about each region & countries covered in the report. Identifying its production, consumption, import & export, sales volume & revenue forecast.

**Market Analysis by Product Type:** The report covers majority Product Types in the Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Industry, including its product specifications by each key player, volume, sales by Volume and Value (M USD).

**Market Analysis by Application Type:** Based on the Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Industry and its applications, the market is further sub-segmented into several major Application of its industry. It provides you with the market size, CAGR & forecast by each industry applications.

**Market Trends:** Market key trends which include Increased Competition and Continuous Innovations.

**Opportunities and Drivers:** Identifying the Growing Demands and New Technology

**Porters Five Force Analysis:** The report will provide with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

#### COVID-19 Impact

Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global

impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

## Contents

### 1 REPORT OVERVIEW

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue

1.4 Market Analysis by Type

1.4.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 Chemotherapy

1.4.3 Peptide-Receptor Radionuclide Therapy

1.4.4 Others

1.5 Market by Application

1.5.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application: 2021-2026

1.5.2 Hospitals

1.5.3 Clinics

1.5.4 Ambulatory Surgical Centers

1.5.5 Others

1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth

1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections

1.6.2 Covid-19 Impact: Commodity Prices Indices

1.6.3 Covid-19 Impact: Global Major Government Policy

1.7 Study Objectives

1.8 Years Considered

### 2 GLOBAL GROWTH TRENDS

2.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Perspective (2021-2026)

2.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Growth Trends by Regions

2.2.1 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Regions: 2015 VS 2021 VS 2026

2.2.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Size by Regions (2015-2020)

2.2.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Regions (2021-2026)

### **3 MARKET COMPETITION BY MANUFACTURERS**

3.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production Capacity Market Share by Manufacturers (2015-2020)

3.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Manufacturers (2015-2020)

3.3 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Average Price by Manufacturers (2015-2020)

### **4 GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS PRODUCTION BY REGIONS**

#### 4.1 North America

4.1.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2015-2026)

4.1.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Key Players in North America (2015-2020)

4.1.3 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2015-2020)

4.1.4 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2015-2020)

#### 4.2 East Asia

4.2.1 East Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2015-2026)

4.2.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Key Players in East Asia (2015-2020)

4.2.3 East Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2015-2020)

4.2.4 East Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2015-2020)

#### 4.3 Europe

4.3.1 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2015-2026)

4.3.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Key Players in Europe (2015-2020)

4.3.3 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market

## Size by Type (2015-2020)

### 4.3.4 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market

## Size by Application (2015-2020)

## 4.4 South Asia

### 4.4.1 South Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2015-2026)

### 4.4.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Key Players in South Asia (2015-2020)

### 4.4.3 South Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2015-2020)

### 4.4.4 South Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2015-2020)

## 4.5 Southeast Asia

### 4.5.1 Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2015-2026)

### 4.5.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Key Players in Southeast Asia (2015-2020)

### 4.5.3 Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2015-2020)

### 4.5.4 Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2015-2020)

## 4.6 Middle East

### 4.6.1 Middle East Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2015-2026)

### 4.6.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Key Players in Middle East (2015-2020)

### 4.6.3 Middle East Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2015-2020)

### 4.6.4 Middle East Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2015-2020)

## 4.7 Africa

### 4.7.1 Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2015-2026)

### 4.7.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Key Players in Africa (2015-2020)

### 4.7.3 Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2015-2020)

### 4.7.4 Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2015-2020)



#### 4.8 Oceania

4.8.1 Oceania Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2015-2026)

4.8.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Key Players in Oceania (2015-2020)

4.8.3 Oceania Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2015-2020)

4.8.4 Oceania Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2015-2020)

#### 4.9 South America

4.9.1 South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2015-2026)

4.9.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Key Players in South America (2015-2020)

4.9.3 South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2015-2020)

4.9.4 South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2015-2020)

#### 4.10 Rest of the World

4.10.1 Rest of the World Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2015-2026)

4.10.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Key Players in Rest of the World (2015-2020)

4.10.3 Rest of the World Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2015-2020)

4.10.4 Rest of the World Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2015-2020)

## **5 GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS CONSUMPTION BY REGION**

#### 5.1 North America

5.1.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption by Countries

5.1.2 United States

5.1.3 Canada

5.1.4 Mexico

#### 5.2 East Asia

5.2.1 East Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics

## Consumption by Countries

5.2.2 China

5.2.3 Japan

5.2.4 South Korea

## 5.3 Europe

5.3.1 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics

## Consumption by Countries

5.3.2 Germany

5.3.3 United Kingdom

5.3.4 France

5.3.5 Italy

5.3.6 Russia

5.3.7 Spain

5.3.8 Netherlands

5.3.9 Switzerland

5.3.10 Poland

## 5.4 South Asia

5.4.1 South Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics

## Consumption by Countries

5.4.2 India

5.4.3 Pakistan

5.4.4 Bangladesh

## 5.5 Southeast Asia

5.5.1 Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics

## Consumption by Countries

5.5.2 Indonesia

5.5.3 Thailand

5.5.4 Singapore

5.5.5 Malaysia

5.5.6 Philippines

5.5.7 Vietnam

5.5.8 Myanmar

## 5.6 Middle East

5.6.1 Middle East Gastroenteropancreatic Neuroendocrine Tumor Therapeutics

## Consumption by Countries

5.6.2 Turkey

5.6.3 Saudi Arabia

5.6.4 Iran

5.6.5 United Arab Emirates

5.6.6 Israel

5.6.7 Iraq

5.6.8 Qatar

5.6.9 Kuwait

5.6.10 Oman

5.7 Africa

5.7.1 Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics

Consumption by Countries

5.7.2 Nigeria

5.7.3 South Africa

5.7.4 Egypt

5.7.5 Algeria

5.7.6 Morocco

5.8 Oceania

5.8.1 Oceania Gastroenteropancreatic Neuroendocrine Tumor Therapeutics

Consumption by Countries

5.8.2 Australia

5.8.3 New Zealand

5.9 South America

5.9.1 South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics

Consumption by Countries

5.9.2 Brazil

5.9.3 Argentina

5.9.4 Columbia

5.9.5 Chile

5.9.6 Venezuela

5.9.7 Peru

5.9.8 Puerto Rico

5.9.9 Ecuador

5.10 Rest of the World

5.10.1 Rest of the World Gastroenteropancreatic Neuroendocrine Tumor Therapeutics

Consumption by Countries

5.10.2 Kazakhstan

## **6 GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS SALES MARKET BY TYPE (2015-2026)**

6.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Size by Type (2015-2020)

6.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Type (2021-2026)

## **7 GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS CONSUMPTION MARKET BY APPLICATION(2015-2026)**

7.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Size by Application (2015-2020)

7.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Application (2021-2026)

## **8 COMPANY PROFILES AND KEY FIGURES IN GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR THERAPEUTICS BUSINESS**

8.1 Novartis

8.1.1 Novartis Company Profile

8.1.2 Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Specification

8.1.3 Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.2 Tarveda Therapeutics

8.2.1 Tarveda Therapeutics Company Profile

8.2.2 Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Specification

8.2.3 Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.3 Teva Pharmaceuticals

8.3.1 Teva Pharmaceuticals Company Profile

8.3.2 Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Specification

8.3.3 Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.4 Pfizer

8.4.1 Pfizer Company Profile

8.4.2 Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Specification

8.4.3 Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.5 Exelixis, Inc.

8.5.1 Exelixis, Inc. Company Profile

8.5.2 Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics  
Product Specification

8.5.3 Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics  
Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.6 Fresenius Kabi

8.6.1 Fresenius Kabi Company Profile

8.6.2 Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics  
Product Specification

8.6.3 Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics  
Production Capacity, Revenue, Price and Gross Margin (2015-2020)

8.7 Hutchison China MediTech Limited

8.7.1 Hutchison China MediTech Limited Company Profile

8.7.2 Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine  
Tumor Therapeutics Product Specification

8.7.3 Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine  
Tumor Therapeutics Production Capacity, Revenue, Price and Gross Margin  
(2015-2020)

8.8 Sun Pharma

8.8.1 Sun Pharma Company Profile

8.8.2 Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics  
Product Specification

8.8.3 Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics  
Production Capacity, Revenue, Price and Gross Margin (2015-2020)

## **9 PRODUCTION AND SUPPLY FORECAST**

9.1 Global Forecasted Production of Gastroenteropancreatic Neuroendocrine Tumor  
Therapeutics (2021-2026)

9.2 Global Forecasted Revenue of Gastroenteropancreatic Neuroendocrine Tumor  
Therapeutics (2021-2026)

9.3 Global Forecasted Price of Gastroenteropancreatic Neuroendocrine Tumor  
Therapeutics (2015-2026)

9.4 Global Forecasted Production of Gastroenteropancreatic Neuroendocrine Tumor  
Therapeutics by Region (2021-2026)

9.4.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics  
Production, Revenue Forecast (2021-2026)

9.4.2 East Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics  
Production, Revenue Forecast (2021-2026)

9.4.3 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production, Revenue Forecast (2021-2026)

9.4.4 South Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production, Revenue Forecast (2021-2026)

9.4.5 Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production, Revenue Forecast (2021-2026)

9.4.6 Middle East Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production, Revenue Forecast (2021-2026)

9.4.7 Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production, Revenue Forecast (2021-2026)

9.4.8 Oceania Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production, Revenue Forecast (2021-2026)

9.4.9 South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production, Revenue Forecast (2021-2026)

9.4.10 Rest of the World Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production, Revenue Forecast (2021-2026)

9.5 Forecast by Type and by Application (2021-2026)

9.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)

9.5.2 Global Forecasted Consumption of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics by Application (2021-2026)

## **10 CONSUMPTION AND DEMAND FORECAST**

10.1 North America Forecasted Consumption of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics by Country

10.2 East Asia Market Forecasted Consumption of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics by Country

10.3 Europe Market Forecasted Consumption of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics by Country

10.4 South Asia Forecasted Consumption of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics by Country

10.5 Southeast Asia Forecasted Consumption of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics by Country

10.6 Middle East Forecasted Consumption of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics by Country

10.7 Africa Forecasted Consumption of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics by Country

10.8 Oceania Forecasted Consumption of Gastroenteropancreatic Neuroendocrine

Tumor Therapeutics by Country

10.9 South America Forecasted Consumption of Gastroenteropancreatic  
Neuroendocrine Tumor Therapeutics by Country

10.10 Rest of the world Forecasted Consumption of Gastroenteropancreatic  
Neuroendocrine Tumor Therapeutics by Country

## **11 MARKETING CHANNEL, DISTRIBUTORS AND CUSTOMERS**

11.1 Marketing Channel

11.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Distributors List

11.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Customers

## **12 INDUSTRY TRENDS AND GROWTH STRATEGY**

12.1 Market Top Trends

12.2 Market Drivers

12.3 Market Challenges

12.4 Porter's Five Forces Analysis

12.5 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Growth  
Strategy

## **13 ANALYST'S VIEWPOINTS/CONCLUSIONS**

## **14 APPENDIX**

14.1 Research Methodology

14.1.1 Methodology/Research Approach

14.1.2 Data Source

14.2 Disclaimer



## List Of Tables

### LIST OF TABLES AND FIGURES

Table 1. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type: 2020 VS 2026

Table 2. Chemotherapy Features

Table 3. Peptide-Receptor Radionuclide Therapy Features

Table 4. Others Features

Table 11. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application: 2020 VS 2026

Table 12. Hospitals Case Studies

Table 13. Clinics Case Studies

Table 14. Ambulatory Surgical Centers Case Studies

Table 15. Others Case Studies

Table 21. Commodity Prices-Metals Price Indices

Table 22. Commodity Prices- Precious Metal Price Indices

Table 23. Commodity Prices- Agricultural Raw Material Price Indices

Table 24. Commodity Prices- Food and Beverage Price Indices

Table 25. Commodity Prices- Fertilizer Price Indices

Table 26. Commodity Prices- Energy Price Indices

Table 27. G20+: Economic Policy Responses to COVID-19

Table 28. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Report Years Considered

Table 29. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth 2021-2026 (US\$ Million)

Table 30. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Regions: 2021 VS 2026

Table 31. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2015-2026) (US\$ Million)

Table 32. East Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2015-2026) (US\$ Million)

Table 33. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2015-2026) (US\$ Million)

Table 34. South Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2015-2026) (US\$ Million)

Table 35. Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2015-2026) (US\$ Million)

Table 36. Middle East Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2015-2026) (US\$ Million)



Table 37. Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2015-2026) (US\$ Million)

Table 38. Oceania Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2015-2026) (US\$ Million)

Table 39. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2015-2026) (US\$ Million)

Table 40. Rest of the World Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2015-2026) (US\$ Million)

Table 41. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption by Countries (2015-2020)

Table 42. East Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption by Countries (2015-2020)

Table 43. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption by Region (2015-2020)

Table 44. South Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption by Countries (2015-2020)

Table 45. Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption by Countries (2015-2020)

Table 46. Middle East Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption by Countries (2015-2020)

Table 47. Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption by Countries (2015-2020)

Table 48. Oceania Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption by Countries (2015-2020)

Table 49. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption by Countries (2015-2020)

Table 50. Rest of the World Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption by Countries (2015-2020)

Table 51. Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Specification

Table 52. Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Specification

Table 53. Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Specification

Table 54. Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Specification

Table 55. Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Specification

Table 56. Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics

## Product Specification

Table 57. Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Specification

Table 58. Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Specification

Table 101. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production Forecast by Region (2021-2026)

Table 102. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Sales Volume Forecast by Type (2021-2026)

Table 103. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Sales Volume Market Share Forecast by Type (2021-2026)

Table 104. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Sales Revenue Forecast by Type (2021-2026)

Table 105. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Sales Revenue Market Share Forecast by Type (2021-2026)

Table 106. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Sales Price Forecast by Type (2021-2026)

Table 107. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Volume Forecast by Application (2021-2026)

Table 108. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Value Forecast by Application (2021-2026)

Table 109. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Forecast 2021-2026 by Country

Table 110. East Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Forecast 2021-2026 by Country

Table 111. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Forecast 2021-2026 by Country

Table 112. South Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Forecast 2021-2026 by Country

Table 113. Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Forecast 2021-2026 by Country

Table 114. Middle East Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Forecast 2021-2026 by Country

Table 115. Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Forecast 2021-2026 by Country

Table 116. Oceania Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Forecast 2021-2026 by Country

Table 117. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Forecast 2021-2026 by Country

Table 118. Rest of the world Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Forecast 2021-2026 by Country

Table 119. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Distributors List

Table 120. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Customers List

Table 121. Porter's Five Forces Analysis

Table 122. Key Executives Interviewed

Figure 1. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 2. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Market Share by Countries in 2020

Figure 3. United States Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 4. Canada Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 5. Mexico Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 6. East Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 7. East Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Market Share by Countries in 2020

Figure 8. China Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 9. Japan Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 10. South Korea Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 11. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate

Figure 12. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Market Share by Region in 2020

Figure 13. Germany Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 14. United Kingdom Gastroenteropancreatic Neuroendocrine Tumor

Therapeutics Consumption and Growth Rate (2015-2020)

Figure 15. France Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 16. Italy Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 17. Russia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 18. Spain Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 19. Netherlands Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 20. Switzerland Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 21. Poland Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 22. South Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate

Figure 23. South Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Market Share by Countries in 2020

Figure 24. India Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 25. Pakistan Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 26. Bangladesh Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 27. Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate

Figure 28. Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Market Share by Countries in 2020

Figure 29. Indonesia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 30. Thailand Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 31. Singapore Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 32. Malaysia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 33. Philippines Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 34. Vietnam Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 35. Myanmar Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 36. Middle East Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate

Figure 37. Middle East Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Market Share by Countries in 2020

Figure 38. Turkey Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 39. Saudi Arabia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 40. Iran Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 41. United Arab Emirates Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 42. Israel Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 43. Iraq Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 44. Qatar Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 45. Kuwait Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 46. Oman Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 47. Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate

Figure 48. Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Market Share by Countries in 2020

Figure 49. Nigeria Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 50. South Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 51. Egypt Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 52. Algeria Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 53. Morocco Gastroenteropancreatic Neuroendocrine Tumor Therapeutics



Consumption and Growth Rate (2015-2020)

Figure 54. Oceania Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate

Figure 55. Oceania Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Market Share by Countries in 2020

Figure 56. Australia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 57. New Zealand Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 58. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate

Figure 59. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Market Share by Countries in 2020

Figure 60. Brazil Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 61. Argentina Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 62. Columbia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 63. Chile Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 64. Venezuelal Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 65. Peru Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 66. Puerto Rico Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 67. Ecuador Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 68. Rest of the World Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate

Figure 69. Rest of the World Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption Market Share by Countries in 2020

Figure 70. Kazakhstan Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Consumption and Growth Rate (2015-2020)

Figure 71. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production Capacity Growth Rate Forecast (2021-2026)

Figure 72. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Growth Rate Forecast (2021-2026)

Figure 73. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Price and Trend Forecast (2015-2026)

Figure 74. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production Growth Rate Forecast (2021-2026)

Figure 75. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Growth Rate Forecast (2021-2026)

Figure 76. East Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production Growth Rate Forecast (2021-2026)

Figure 77. East Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Growth Rate Forecast (2021-2026)

Figure 78. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production Growth Rate Forecast (2021-2026)

Figure 79. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Growth Rate Forecast (2021-2026)

Figure 80. South Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production Growth Rate Forecast (2021-2026)

Figure 81. South Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Growth Rate Forecast (2021-2026)

Figure 82. Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production Growth Rate Forecast (2021-2026)

Figure 83. Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Growth Rate Forecast (2021-2026)

Figure 84. Middle East Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production Growth Rate Forecast (2021-2026)

Figure 85. Middle East Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Growth Rate Forecast (2021-2026)

Figure 86. Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production Growth Rate Forecast (2021-2026)

Figure 87. Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Growth Rate Forecast (2021-2026)

Figure 88. Oceania Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production Growth Rate Forecast (2021-2026)

Figure 89. Oceania Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Growth Rate Forecast (2021-2026)

Figure 90. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Production Growth Rate Forecast (2021-2026)

Figure 91. South America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Growth Rate Forecast (2021-2026)

Figure 92. Rest of the World Gastroenteropancreatic Neuroendocrine Tumor

Therapeutics Production Growth Rate Forecast (2021-2026)

Figure 93. Rest of the World Gastroenteropancreatic Neuroendocrine Tumor

Therapeutics Revenue Growth Rate Forecast (2021-2026)

Figure 94. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics

Consumption Forecast 2021-2026

Figure 95. East Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics

Consumption Forecast 2021-2026

Figure 96. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics

Consumption Forecast 2021-2026

Figure 97. South Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics

Consumption Forecast 2021-2026

Figure 98. Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics

Consumption Forecast 2021-2026

Figure 99. Middle East Gastroenteropancreatic Neuroendocrine Tumor Therapeutics

Consumption Forecast 2021-2026

Figure 100. Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics

Consumption Forecast 2021-2026

Figure 101. Oceania Gastroenteropancreatic Neuroendocrine Tumor Therapeutics

Consumption Forecast 2021-2026

Figure 102. South America Gastroenteropancreatic Neuroendocrine Tumor

Therapeutics Consumption Forecast 2021-2026

Figure 103. Rest of the world Gastroenteropancreatic Neuroendocrine Tumor

Therapeutics Consumption Forecast 2021-2026

Figure 104. Channels of Distribution

Figure 105. Distributors Profiles



## I would like to order

Product name: Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Insight and Forecast to 2026

Product link: <https://marketpublishers.com/r/G6B801AB51ACEN.html>

Price: US\$ 2,350.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6B801AB51ACEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

